Accelerated Approval Withdrawals Through The Years

25 Apr 2019

Lartruvo’s brief time on the market is especially quick compared with other drugs and indications that received accelerated approval from the US FDA and were subsequently withdrawn, our infographic shows.

This is a companion infographic to our main story about Eli Lilly & Co.’s withdrawal of its soft tissue sarcoma treatment Lartruvo (olaratumab) from markets worldwide. The information is based on US Food and Drug Administration data compiled by the Pink Sheet.

Open Media